MeDucation· @MeDucationai · X·· 4 天前评分70
正文 · 机器翻译
@HHorinouchi's FLAURA2 总结传达了当天的教学要点：早期血浆 EGFRm 清除具有预后意义，但不具有预测意义，因此不应以此作为在 osimertinib 治疗中加用或跳过化疗的理由。#ESMO26 #LCSM
42 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associated Clinical Outcomes in Patients (Pts) With EGFRm Advanced NSCLC Treated With First-Line (1L) Osimertinib (Osi) ± Platinum–Pemetrexed (Plat–Pem) 🎙️ @dplanchard 🔢2719RO 🎯EGFRm Clearance Prognostic but Not Predictive 🎯Osi+Plat–Pem Benefit Over Osi Alone Consistent Regardless of Clearance Status at Wk 1, 2, 3, 6; Clearance Rates Comparable Between Arms ☑️NCT04035486 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters在 X 查看被引用的帖子
来源：MeDucation · x.com